Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features (PMD)
Brief Summary: Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).


Options:
A: Arm Label: olanzapine/sertraline combination; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Sertraline | Arm Label: olanzapine plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olanzapine, Other: placebo | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): olanzapine plus placebo, olanzapine/sertraline combination | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): olanzapine/sertraline combination | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): olanzapine plus placebo
B: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matching placebo
C: Arm Label: mifepristone 300 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: mifepristone matched placebo | Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 600 mg | Arm Label: mifepristone 1200 mg; Type: EXPERIMENTAL; Interventions: Drug: mifepristone 1200 mg | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone 300 mg | Intervention Type: DRUG; Name: mifepristone matched placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: mifepristone 600 mg; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: mifepristone 1200 mg; Assigned to Arm(s): mifepristone 1200 mg
D: Arm Label: mifepristone 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Arm Label: matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): mifepristone 600 mg | Intervention Type: DRUG; Name: matching placebo; Assigned to Arm(s): matching placebo

Answer: C